BRISTOL MYERS SQUIBB CO (BMY) vs JOHNSON & JOHNSON (JNJ)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BMY | JNJ |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $48.19B | $94.19B |
| Revenue growth (YoY) | ▼ 0.2% | ▲ 6.0% |
| Net income | $7.05B | $26.8B |
| Gross margin | 71.1% | 67.9% |
| Diluted EPS | $3.46 | $11.03 |
| Insider net (6 mo) | +46.8K sh • 2 sells • 0 buys | −40.8K sh • 7 sells • 0 buys |
| Institutional owners | 47 | 47 |
| Institutional value held | $63.76B | $294.77B |
| Next earnings (est.) | Oct 29, 2026 | Around Jan 20, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BRISTOL MYERS SQUIBB CO (BMY)
Bristol-Myers Squibb Company, incorporated in Delaware in 1933 as successor to a New York business dating to 1887 and renamed following a 1989 merger, is a biopharmaceutical company operating in a single segment focused on discovering, developing… Read more →
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson, incorporated in New Jersey in 1887, is a global healthcare holding company with approximately 138,200 full-time-equivalent employees engaged in the research, development, manufacture, and sale of a broad range of healthcare products. Read more →
Source: SEC EDGAR.